Medical/Pharmaceuticals
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance ...
2025-02-26 08:03
2747
Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
HEFEI, China, Feb. 25, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory...
2025-02-25 21:00
2590
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces reaching agreements with an investment fund m...
2025-02-25 21:00
3061
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
4268
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
* Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued progression as planned * MRX-4 Injection followed by Contezolid Tablets demonstrated favorable safety and efficacy profiles in patients with...
2025-02-25 18:44
3365
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced the si...
2025-02-25 18:34
2564
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing investigator-initiated trial (IIT) of YOLT-203 in patients with ...
2025-02-25 16:15
2435
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD) cohort of its randomized, double-blind, placebo...
2025-02-25 14:48
12972
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results supportsugemalimab in combination with chemotherapy as a new standard first-line treatmentfor patients wit...
2025-02-25 12:10
3688
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investi...
2025-02-25 09:13
2731
Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy
TORONTO, Feb. 24, 2025 /PRNewswire/ -- In today's era of rapid technological advancement, the deep integration of artificial intelligence and the medical field is bringing unprecedented hope to human health. Among these advancements, targeted therapy, a cornerstone of precision medicine, is gradu...
2025-02-24 22:00
2807
Complete Genomics unveils DNBSEQ-T1+ and DNBSEQ-E25 Flash at AGBT 2025 General Meeting
MARCO ISLAND, Fla., Feb. 24, 2025 /PRNewswire/ -- Complete Genomics, a leading
innovator in genomic sequencing, today unveiled its latest high-performance
sequencing solutions at the 2025Advances in Genome Biology and Technology
(AGBT) General Meeting
2025-02-24 20:00
2756
MGI Tech Closes Strategic Partnership with Oncoclínicas&Co to Contribute to Genomic Innovation in Oncological Health
Agreement contributes to expanding access to cutting-edge genomic technologies and improving diagnostic efficacy SÃO PAULO, Feb. 23, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, established a p...
2025-02-24 11:15
2696
Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- On February 15, 2025, Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a library capacity of up to 10 trillion, ...
2025-02-23 18:00
4023
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics
2025-02-21 21:15
3997
Coreline Soft Leads AI Medical Imaging Innovation at STR 2025
* Introducing the AVIEW lineup specialized in simultaneous diagnosis and
analysis of thoracic diseases
* Participating in HIMSS on March 3rd and completing HIPAA certification
HUNTINGTON BEACH, Calif. and SEOUL, South Korea, Feb. 21, 2025 /PRNewswire/ --
Coreline Soft
2025-02-21 21:00
4842
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line tr...
2025-02-21 08:47
3181
Bestqool Unveils Four-Wavelength Pro Series and Second-Gen Mobile Stand at Original Price
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- In a recent announcement, Bestqool is
upgrading both the Pro100 and Pro200 to the four-wavelength configuration (630
nm, 660 nm, 850 nm, 940 nm) as the Pro 300
2025-02-21 01:09
3299
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
* YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 * First-in-class novel PTH replacement therapy * Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH s...
2025-02-21 00:01
4532
NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test
SEOUL, South Korea, Feb. 20, 2025 /PRNewswire/ -- PranaQ, backed by NAVER D2SF continues to push the boundaries of AI-powered healthcare solutions. NAVER D2SF, NAVER's corporate venturing arm, actively collaborates with startups to drive innovation and sustainable growth. This investment undersco...
2025-02-21 00:00
3460
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 279 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Amap and Sands China mark the delivery of the first Tutu robots, with expected indoor navigation and 3D resort previews
2026-10-10 16:43
16726
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
16655
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
14362
Zoomlion Expands Mining Machinery Business as International Revenue Grows
2026-10-10 16:58
8354
